Davis Polk, Slaughter & May Steer GSK's $10.6B Nuvalent Deal
By Dawood Fakhir · June 9, 2026, 12:29 PM BST
Pharma giant GSK PLC said Tuesday that it has agreed to acquire cancer therapy specialist Nuvalent Inc. for $10.6 billion as it seeks to accelerate its "rapid expansion" into the oncology...
To view the full article, register now.